Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force
1 Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA
2 Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle, WA, USA
3 Cancer Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
4 Society for Immunotherapy of Cancer and Executive Director, Inc., Milwaukee, WI, USA
5 Infectious Disease and Immunogenetics Section (IDIS), Dept. of Translation Medicine, Clinical Center, and Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA
Journal of Translational Medicine 2010, 8:130 doi:10.1186/1479-5876-8-130Published: 7 December 2010
The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.